Orthodontically induced root and alveolar bone resorption: inhibitory effect of systemic doxycycline administration in rats.
The aim of the present study was to investigate the effect of systemic administration of low-dose doxycycline (DC) on orthodontic root resorption. The effect on alveolar bone, the cell population involved, and the amount of tooth movement were also evaluated.Fifty-six 40-50-day-old male Wistar rats were used. Six animals served as untreated controls. Six animals were only administered DC for 7 days, by means of a mini-osmotic pump implanted subcutaneously. In 44 animals the maxillary first molar was mesialized by a fixed orthodontic appliance exerting 50 g force upon insertion. In 28 of these animals DC was administered at the time of appliance insertion and throughout the experiment. The animals were sacrificed 7, 10 or 14 days after force application and block sections processed for analysis. An area including the mesial aspect of the distopalatal root and the adjacent inter-radicular alveolar bone was histomorphometrically evaluated. The root resorption area, absolute alveolar bone area, distance between first and second molars, number of odontoclasts, osteoclasts, mononuclear cells on the root, tartrate-resistant acid phosphatase (TRAP)-positive cells on the root, bone, and in the periodontal ligament (PDL) were compared between DC-treated and non-DC-treated animals. The results revealed a significant reduction in root resorption, the number of odontoclasts, osteoclasts, mononuclear cells on the root surface, and TRAP-positive cells on the root and bone for the DC-administered group. The absolute alveolar bone area was greater, whereas the distance between the first and second molars did not differ between groups. In conclusion, systemic administration of low-dose DC in rats may have an inhibitory effect on orthodontically induced resorptive activity.
Mavragani
Maria
M
Department of Dental Research, Faculty of Dentistry, University of Bergen, Arstadveien 17, N-5009 Bergen, Norway. maria.mavragani@odont.uib.no
Brudvik
Pongsri
P
Selvig
Knut Andreas
KA
D000135:Acid Phosphatase / Q000032:analysis; D016301:Alveolar Bone Loss / Q000517:prevention & control*; D000539:Alveolar Process / Q000187:drug effects / Q000473:pathology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis; D004318:Doxycycline / Q000008:administration & dosage / Q000627:therapeutic use*; D007260:Infusion Pumps; D007279:Injections, Subcutaneous / Q000295:instrumentation; D007527:Isoenzymes / Q000032:analysis; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000473:pathology; D008297:Male; D008963:Molar / Q000187:drug effects / Q000473:pathology; D010010:Osteoclasts / Q000187:drug effects / Q000473:pathology; D010513:Periodontal Ligament / Q000187:drug effects / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D012391:Root Resorption / Q000517:prevention & control*; D000071681:Tartrate-Resistant Acid Phosphatase; D014087:Tooth Movement Techniques / Q000009:adverse effects* / Q000295:instrumentation; D014092:Tooth Root / Q000187:drug effects / Q000473:pathology
D000900:Anti-Bacterial Agents; D015415:Biomarkers; D007527:Isoenzymes; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; D004318:Doxycycline